Abstract
The paper presents a novel approach to prediction of the combined therapy outcome for non-small lung cancer patients. A hybrid model is proposed, consisting of two parts. The first one is a mathematical model of tumor response to therapy, whose parameters are expressed as a linear functions of data from mass spectrometry of patient blood plasma samples. These linear functions constitute the second component of the hybrid model. A comparison of clinical and simulation-based survival curves is used to evaluate the quality of the model.
| Translated title of the contribution | Predykcja odpowiedzi na kombinowaną terapiędla niedrobnokomórkowego raka płuc przy użyciu modelu hybrydowego |
|---|---|
| Original language | English |
| Pages (from-to) | 219-228 |
| Number of pages | 10 |
| Journal | Mathematica Applicanda |
| Volume | 47 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Combined therapy
- Lung cancer
- Survival analysis
- Therapy response prediction
ASJC Scopus subject areas
- General Mathematics
- Decision Sciences (miscellaneous)
Fingerprint
Dive into the research topics of 'Prediction of lung cancer patients' response to combined chemo-radiotherapy using a personalized hybrid model'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver